LeonaBio (LONA) Long-Term Deferred Tax (2022 - 2023)
LeonaBio (LONA) reported Long-Term Deferred Tax of $25.2 million for Q4 2023, up 135.51% year-over-year from $10.7 million in Q4 2022, and up 135.51% on a QoQ basis from $10.7 million in Q4 2022.
LeonaBio (LONA) has 2 years of Long-Term Deferred Tax data on file, last reported at $25.2 million in Q4 2023.
- Quarterly Long-Term Deferred Tax rose 135.51% year-over-year to $25.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $25.2 million (up 135.51% YoY) and the FY2023 annual result came in at $25.2 million, up 135.51% from the prior year.
- Long-Term Deferred Tax climbed to $25.2 million in Q4 2023 per LONA's latest filing, from $10.7 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $25.2 million in Q4 2023 and bottomed at $10.7 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | LeonaBio | 181.52 Mn | 113.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 25.20 Mn |
| Dec 31, 2022 | 10.70 Mn |